Kornitzer Capital Management Inc. KS Lowers Stock Holdings in Insulet Corporation $PODD

Posted by George Bondi on Jul 12th, 2026

Kornitzer Capital Management Inc. KS reduced its stake in Insulet Corporation (NASDAQ:PODD – Free Report) by 17.3% during the first quarter, HoldingsChannel.com reports. The firm owned 15,300 shares of the medical instruments supplier’s stock after selling 3,200 shares during the quarter. Kornitzer Capital Management Inc. KS’s holdings in Insulet were worth $3,211,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Glenmede Investment Management LP raised its stake in Insulet by 1.6% during the third quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock valued at $708,000 after buying an additional 35 shares during the last quarter. Curi Capital LLC raised its position in shares of Insulet by 0.8% in the 2nd quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock worth $1,365,000 after purchasing an additional 36 shares during the last quarter. Great Lakes Advisors LLC raised its position in shares of Insulet by 1.5% in the 4th quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier’s stock worth $791,000 after purchasing an additional 40 shares during the last quarter. Camarda Financial Advisors LLC boosted its stake in Insulet by 0.5% in the 2nd quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock worth $2,304,000 after purchasing an additional 40 shares in the last quarter. Finally, Larson Financial Group LLC boosted its stake in Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares in the last quarter.

Insulet Stock Performance

Shares of Insulet stock traded up $2.99 during trading on Friday, hitting $161.28. 723,321 shares of the company’s stock traded hands, compared to its average volume of 1,357,711. Insulet Corporation has a 1 year low of $138.79 and a 1 year high of $354.88. The business has a 50-day simple moving average of $152.93 and a 200-day simple moving average of $211.33. The stock has a market capitalization of $11.17 billion, a P/E ratio of 37.51, a PEG ratio of 1.12 and a beta of 1.11. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD – Get Free Report) last issued its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to analyst estimates of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.Insulet’s revenue was up 33.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, analysts forecast that Insulet Corporation will post 6.46 EPS for the current year.

Insider Activity at Insulet

In related news, Director Timothy C. Stonesifer acquired 2,790 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The stock was purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the acquisition, the director directly owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.36% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on PODD shares. Sanford C. Bernstein reduced their price objective on shares of Insulet from $330.00 to $200.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Barclays decreased their target price on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a report on Thursday, May 7th. The Goldman Sachs Group reiterated a “buy” rating and set a $205.00 price target on shares of Insulet in a report on Wednesday, May 27th. Canaccord Genuity Group reduced their price target on shares of Insulet from $435.00 to $249.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Insulet from $340.00 to $275.00 and set an “overweight” rating for the company in a research report on Thursday, May 7th. Twenty-two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Insulet presently has an average rating of “Moderate Buy” and an average target price of $237.08.

View Our Latest Stock Report on PODD

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

Positive Sentiment: Stifel kept a buy rating on PODD, although it lowered its price target from $250 to $225, suggesting the stock still has meaningful upside despite recent volatility. Benzinga reference
Neutral Sentiment: Insulet also appeared in a positive-style growth note and an article discussing the stock’s valuation after a sharp decline, but these pieces did not provide fresh company-specific catalysts. Yahoo Finance reference
Neutral Sentiment: Short-interest data showed no reported short interest as of July 10, so it does not currently signal a meaningful bearish positioning change.
Negative Sentiment: Several law firms announced or promoted class-action lawsuits against Insulet over alleged securities fraud and Omnipod safety disclosures, which can create investor uncertainty and pressure the stock. PR Newswire reference

About Insulet

(Free Report)

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.